…
Hexima Limited does not have significant operations. It focuses on exploration of transactions with third parties, which could enable the value of the company's assets. Previously, the company was involved in the research and development of plant-derived proteins for applications as human therapeutics. The company was incorporated in 1997 and is based in Carlton, Australia.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Hexima Limited is an Australian life sciences company developing plant-derived peptide technologies for crop protection and human health applications. Its long-term growth may be driven by successful R&D outcomes, commercialization or licensing of its intellectual property and wider industry adoption of peptide-based solutions. Investors may find the company attractive for its differentiated platform and potential to generate scalable licensing and product revenues if development milestones are met.
Primary investment risks include early-stage development status with limited commercial revenue, reliance on successful trials and partner or license agreements, ongoing funding needs, and competition from larger biotech and agrochemical firms.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
| Income before tax | -0.22M | -0.50M | -0.50M | -1.00M | -1.00M |
| Net income | -0.22M | -0.50M | -0.50M | -0.93M | -0.93M |
| Selling general administrative | 0.23M | 0.23M | 0.23M | 0.29M | 0.29M |
| Selling and marketing expenses | - | 0.06M | 0.06M | 0.26M | 0.26M |
| Ebit | -0.26M | - | - | -1.01M | -1.01M |
| Ebitda | -0.26M | - | - | -1.00M | -1.00M |
| Depreciation and amortization | - | 0.32M | 0.32M | 0.01M | 0.01M |
| Operating income | -0.26M | -0.29M | -0.29M | -1.01M | -1.01M |
| Other operating expenses | - | 0.29M | 0.29M | 1.01M | 1.01M |
| Tax provision | 0.00M | - | 0.00M | 0.00M | 0.00M |
| Interest income | 0.04M | - | 0.05M | 0.04M | 0.04M |
| Net interest income | 0.04M | - | - | 0.04M | 0.04M |
| Income tax expense | - | - | - | -0.06M | -0.06M |
| Total revenue | - | - | 0.00M | - | 0.06M |
| Total operating expenses | - | 0.29M | 0.29M | 1.01M | 1.01M |
| Total other income expense net | -0.00M | -0.22M | -0.22M | 0.01M | 0.01M |
| Net income from continuing ops | -0.22M | - | - | -0.93M | -0.93M |
| Net income applicable to common shares | - | - | -0.50M | - | -0.93M |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
| Total assets | 0.28M | 1.56M | 1.56M | 2.27M | 2.27M |
| Other current assets | - | 0.01M | 0.01M | - | - |
| Total liab | 0.04M | 0.04M | 0.04M | 0.25M | 0.25M |
| Total stockholder equity | 0.24M | 1.52M | 1.52M | 2.02M | 2.02M |
| Other current liab | - | 0.03M | 0.03M | 0.14M | 0.14M |
| Common stock | - | 82.88M | 82.88M | 82.88M | 82.88M |
| Capital stock | 81.82M | - | - | 82.88M | - |
| Retained earnings | -82.67M | -82.44M | -82.44M | -81.95M | -81.95M |
| Cash | 0.26M | 1.54M | 1.54M | 2.23M | 2.23M |
| Total current liabilities | 0.04M | 0.04M | 0.04M | 0.25M | 0.25M |
| Net debt | - | -1.54M | -1.54M | -2.23M | -2.23M |
| Total current assets | 0.28M | 1.56M | 1.56M | 2.27M | 2.27M |
| Net receivables | - | 0.01M | 0.01M | 0.04M | 0.04M |
| Accounts payable | 0.01M | 0.01M | 0.01M | 0.11M | 0.11M |
| Accumulated other comprehensive income | - | 1.08M | 1.08M | 1.09M | 1.09M |
| Non current assets total | 0.00M | - | - | 0.00M | - |
| Breakdown | 2026-06-30 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2026-06-30 | 2025-06-30 | 2024-12-31 | 2024-06-30 | 2023-12-31 |
| Investments | - | - | - | - | 0.14M |
| Total cashflows from investing activities | - | 0.05M | 0.05M | 0.10M | 0.10M |
| Total cash from financing activities | -1.06M | -0.10M | -0.10M | 0.10M | 0.10M |
| Net income | -0.22M | -0.50M | -0.50M | -0.93M | -0.93M |
| Change in cash | -1.28M | -0.69M | -0.69M | 0.04M | 0.04M |
| Begin period cash flow | 1.54M | 2.23M | 2.23M | 2.19M | 2.19M |
| End period cash flow | 0.26M | 1.54M | 1.54M | 2.23M | 2.23M |
| Total cash from operating activities | - | -0.64M | -0.64M | -0.16M | -0.16M |
| Other cashflows from investing activities | - | 0.05M | 0.05M | 0.10M | 0.10M |
| Change to account receivables | - | 0.02M | 0.02M | 0.63M | 0.63M |
| Sale purchase of stock | -1.06M | - | - | - | 0.10M |
| Other cashflows from financing activities | - | -0.10M | -0.10M | 0.10M | 0.10M |
| Capital expenditures | 0.00M | 0.00M | 0.00M | 0.00M | 0.00M |
| Change in working capital | - | 0.02M | 0.02M | 0.63M | 0.63M |
| Other non cash items | - | -0.15M | -0.15M | -0.79M | -0.79M |
| Free cash flow | -0.27M | -0.64M | -0.64M | -0.16M | -0.16M |
Sector: Financial Services Industry: Shell Companies
|
Stock Name
|
Change
(AUD) |
Price
(AUD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
Enterprise Value
to EBITDA (x) |
|---|
Hexima Limited does not have significant operations. It focuses on exploration of transactions with third parties, which could enable the value of the company's assets. Previously, the company was involved in the research and development of plant-derived proteins for applications as human therapeutics. The company was incorporated in 1997 and is based in Carlton, Australia.
| Name | Title | Year Born |
|---|---|---|
| Dr. Nicole van der Weerden B.Sc., BSc (Hons), MBA (MBS), Ph.D. | Acting CEO, COO & Exec. Director | NA |
| Ms. Helen Molloy | Financial Controller | NA |
| Prof. Marilyn A. Anderson A.O., AO, B.Sc., BSc (Hons), FAA, FAICD, FT | Chief Science Officer | 1951 |
| Dr. Nancy Sacco | Chief Devel. Officer | NA |
| Ms. Leanne Ralph | Company Sec. | NA |
| Dr. Neil Forrester | VP of Bus. Devel. | NA |
| Prof. Adrienne Elizabeth Clarke | Science Advisor | 1938 |
| Dr. Nancy Sacco | Chief Development Officer | NA |
| Dr. Nancy Sacco | Chief Development Officer | NA |
| Mr. Geoffrey Paul Kempler B.Sc. | MD & Chairman | 1955 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.